Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADVANCESC+: Long-term open-label efgartigimod PH20 SC in adult primary ITP
jRCT2071210087Phase 3Completed
- Sponsor
- argenx
- Start
- Feb 2022
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Therapeutic Enzymes → Recombinant Proteins and Enzymes
01
Overview
Phase 3, open-label, single-arm trial of efgartigimod alfa + hyaluronidase-qvfc in immune thrombocytopenia (ITP), sponsored by argenx. Primary endpoint: Primary safety and tolerability. Started Feb 2022; status: completed.
02
Drugs
efgartigimod alfa + hyaluronidase-qvfc
03
Conditions
immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on jRCT2071210087.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071210087.